There is a quiet shift in how investors view Neimeth International Pharmaceuticals Plc.
The company now attracts strong market attention, and this momentum signals changing sentiment.
Neimeth Valuation And Market Momentum
Its share price has climbed 271% over the past year, and it has gained a further 79% this year.
These gains draw in new investors and soften earlier doubts, while also reshaping the narrative from survival to recovery.
However, the full picture remains more complex than the rally suggests.
The company trades at around 44 times earnings, while earnings per share sit at just ₦0.23.
This valuation typically fits high-growth firms, not recovering businesses like Neimeth.
Meanwhile, the market appears to price in strong future growth, even as the company continues financial restructuring.
Capital Raise And Restructuring
The rally began after Neimeth announced a capital raise in mid-2025.
The company plans to raise ₦20 billion through equity instruments.
When shareholders approved the plan in June 2025, the stock rose by 44%.
Read Also: Property Gains push UH REIT To ₦18.2Bn Profit In 2025
This approval strengthened investor confidence and accelerated the rally.
Now, the company prepares for a court-ordered meeting on March 31.
It seeks approval to restructure its share premium through a scheme of arrangement.
This move aims to strengthen the balance sheet.
Neimeth will offset accumulated losses of ₦1.8 billion against a share premium of ₦2.3 billion, thereby cleaning up past losses.
Debt Pressure And Outlook
At the same time, external debt stands at about ₦8.6 billion, which far exceeds its share capital.
This imbalance highlights ongoing financial pressure.
Although the company returned to profit, risks remain.
It reported a profit after tax of ₦976.4 million.
However, debt costs and foreign exchange pressures drove much of the past losses, and these pressures continue to affect stability.
Revenue has grown strongly, but the company still struggles with financial consistency.
Governance changes and share sales have also raised concerns.
Therefore, the current share price presents both opportunity and risk.
Ultimately, success will depend on execution, debt reduction, and sustained profitability.
